Popular Articles

Diabetes Drug Shows MS Potential
A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss.
generic viagra online
BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions
BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions.
News of the day
Investigation Urgently Needed Into Treatment Of Mentally Ill Immigration Detainees At California Facility, Editorial States
"Although the number of mentally ill immigration detainees" at the La Mesa, Calif.-based private psychiatric hospital Alvarado Parkway Institute "at any one time seems to range from as few as two to only five or so, their situation needs to be addressed quickly," a San Diego Tribune editorial states (San Diego Tribune, 5/19). Some disability rights lawyers and advocates for the mentally ill say that conditions at many of the private facilities, including API, violate state and federal laws governing treatment of mentally ill people. Ann Menasche, a lawyer with the legal advocacy group Disability Rights California, last month sent a letter to the U.S. Immigration and Customs Enforcement claiming that after visiting API and interviewing detainees, she found that the conditions are "excessive, unjustifiable and punitive" (Kaiser Health Disparities Report, 5/18).According to the Tribune, "California"s strict patients" rights laws specify that psychiatric patients can have daily visitors, use the telephone, exercise, socialize and be free from restraint unless the chief of the facility determines that a specific individual is a threat to himself or others," but, according to Menasche, patients at API are being denied those rights. The editorial adds that the conditions Menasche describes "may sound appalling, but it is unclear whether they are proper for the circumstances," and an "independent probe by the state Department of Public Health ... is needed to determine whether the detainees are being treated properly" (San Diego Tribune, 5/19).
Nutrition

Cancer Specialists Back New Treatment For UK Patients

Trial reports of the Evolife range of products in France have pointed to significant benefits and enhanced quality of life for cancer patients who use the products before, during and after chemo or radiotherapy treatment. Evolife is a natural range of cosmetics that is 100% dedicated to the support care of cancer patients. The information comes soon after Feel Better Ltd launched the product range in the UK and Ireland which helps relieve painful skin, nails and other debilitating cutaneous side-effects of anti-cancer treatment. Although British trials are in their early stages, the products have been used in France since 2006 by a number of oncologists, nurses, clinics, hospitals and patients. The range has also been launched in 16 other countries around the world. In the UK the brand is already beginning to stock clinics, such as the Harley St Cancer Clinic, and is providing samples for cancer patient makeovers organised by charities such as Look Good Feel Better and Caroline"s Campaign. Verite Reily Collins is a former cancer patient, journalist and editor of online blog after-cancer.com. She said, "Their Evoskin is a fantastic product; the only one I know that you can use on your face and your body. I didn"t believe this at first, but it works! I also gave some Evomucy to a friend who had mouth ulcers from chemo, and he said it was superb!" Evolife provides solutions to problems that previously had few answers. These include cracked and broken nails (Evonail); flaking and broken skin (Evoskin); mouth ulcers (Evomucy), dry mouth (Evodry) and body odour (Evodeo), to name but a few. The range is currently available in the UK and Republic of Ireland through Feel Better Ltd"s website: www.feelbetterduringchemo.com. Trials in France are far more advanced; Dr Radu Vanica, from the Medical Oncology Department of Argenteuil Hospital, Paris, declared: "On several occasions, we have used Evolife products in our service for treating diverse cutaneous-mucous side effects induced by anti-cancer treatments. "Notably, we have used Evonail on patients presenting side effects on their nails after undergoing two different types of anti-tumour treatment. In both cases, the efficiency of the product and the visible improvement were remarkable. "We also used Evoskin, both the Gel Cream and the Spray formats, on patients suffering from acute outbreaks of acne on their faces and bodies as a result of the anti-tumour treatments. After treating with (the) products, we observed a remarkable improvement of the affected area and patients were able to continue with their therapy as scheduled." Patients who use the treatments often see an improved quality of life whilst undergoing treatment. Annick Courtin, Sister of Chemotherapy at the Hospitalisation a Domicile Service in Laon, added: "Each product has its own specific use and their results are exemplary. Many of these products bring comfort to the patients, for example Evomucy enables the patient to rediscover the pleasure of eating and talking without discomfort. Another product, Evonail, enables patients to feel better about themselves with certain patients rediscovering the need to look after their appearances." The effectiveness of the products on chemotherapy patients was discovered when Dr Geraldine Reynaert, a French dermatologist, was transferred to an oncology clinic in Marseille. She noticed that nail problems caused by cancer treatments were similar to those suffered by the psoriasis patients she had treated previously. She decided to try out the Evaux Laboratories product she had been using. Dr Reynaert said: "In light of the outstanding results achieved, I informed the Evaux Laboratoires research and development team who began to work on a specifically adapted Totum Lithium formula* which eventually became EVONAIL. I then tested this product, successfully, on numerous patients." "Since then, I have helped Evolife Laboratoires with their research into various topics corresponding to the different forms of cutaneous and cutaneo-mucous side effects in chemotherapy and radiotherapy." The range of products is unique to Evolife and distributed in the UK by Feel Better Ltd. Dr Emmanuel Achille from The Claude Bernard Oncology Clinic in Metz said: "We are entirely satisfied with the results obtained by using these products that were easily tolerated by the patients. There is no equivalent to these Evolife products on the pharmaceutical-cosmetics market today." Speaking from the ASCO World Oncology Congress in Orlando where Evolife was being launched in the US, Charles Felgate, joint Managing Director of Feel Better Ltd, said: "The reaction from the medical profession has only been matched by the reaction of cancer patients who have been able to go through chemotherapy and radiotherapy with a greater degree of comfort than before. We are proud to bring a product to the UK market which makes a real difference to people"s lives." *[Totum Lithium describes the unique composition of Evaux-les-Bains spring water] http://www.carolinescampaign.org.uk/ http://www.lookgoodfeelbetter.org/ http://after-cancer.com/category/face-and-skin/


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):